SELLAS Life Sciences SLS
NASDAQ SLS
$11.77 +0.44 (+3.88%)
As of: Oct 2, 2026 · 10:01 AM EDT

SELLAS Life Sciences (SLS) Cash from Financing Activities (2010 - 2026)

Updated

SELLAS Life Sciences (SLS) posted Cash from Financing Activities of $38.83 million for Q2 2026, up 818.1% from $4.23 million a year earlier but down 12.0% from the prior quarter.

Analysis

SELLAS Life Sciences (SLS) Cash from Financing Activities (2010 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Cash from Financing Activities at SELLAS Life Sciences was $141.47 million, up 197.8% year-over-year; for FY2025, it came in at $86.3 million, up 84.6% from FY2024.

  • Annual Cash from Financing Activities shows a five-year compound annual growth rate of 17.6% (FY2020 to FY2025).
  • In prior years, SELLAS Life Sciences' Cash from Financing Activities was $46.76 million in FY2024 (+109.5%), $22.32 million in FY2023 (-7.3%), $24.08 million in FY2022 (+99.4%) and $12.07 million in FY2021 (-68.6%).
  • Quarterly Cash from Financing Activities has run from a low of -$29,000 in Q2 2023 to a high of $44.15 million in Q1 2026 over five years.
  • On a year-over-year basis, Cash from Financing Activities increased in four of the last six quarters, with growth averaging 291.4%.
  • The strongest year-over-year quarter for Cash from Financing Activities in the past five years was Q2 2025, with growth of 921.7%; the weakest was Q4 2021, with a decline of 99.8%.
  • According to Business Quant data, Cash from Financing Activities for the three prior quarters was $44.15 million (Q1 2026), $32.39 million (Q4 2025) and $26.09 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -8.78 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -5.05 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 1.76 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -2.02 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -47.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -1.48 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 2.34 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -3.66 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -426.70 Mn
10 SELLAS Life Sciences 2.49 Bn 2.49 Bn - 38.83 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 38.83 Mn
Mar 31, 2026 44.15 Mn
Dec 31, 2025 32.39 Mn
Sep 30, 2025 26.09 Mn
Jun 30, 2025 4.23 Mn
Mar 31, 2025 23.58 Mn
Dec 31, 2024 8,000.00
Sep 30, 2024 19.69 Mn
Jun 30, 2024 414,000.00
Mar 31, 2024 26.65 Mn
Dec 31, 2023 3.39 Mn
Sep 30, 2023 54,000.00
Jun 30, 2023 -29,000.00
Mar 31, 2023 18.90 Mn
Dec 31, 2022 929,000.00
Sep 30, 2022 107,000.00
Jun 30, 2022 23.00 Mn
Mar 31, 2022 47,000.00
Dec 31, 2021 50,000.00
Sep 30, 2021 2.24 Mn
API Access

SELLAS Life Sciences Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=SLS&period=max&api_key=YOUR_API_KEY